Full Press Release Details
| AmerisourceBergen Corporation | |
| P.O. Box 959 | |
| Valley Forge, PA 19482 |
AMERISOURCEBERGEN REPORTS
FISCAL 2020 SECOND QUARTER RESULTS
Revenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year
Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40
Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020
VALLEY FORGE, PA, May 7, 2020 - AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 second quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7 percent to $2.40 in the fiscal second quarter.
The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously. The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.
"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal 2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to pharmaceuticals in the midst of the COVID-19 pandemic," said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.
AmerisourceBergen's protocols to protect and support the health and wellness of its associates have been enhanced during the COVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued operation of critical business functions.
"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our upstream and downstream partners," Mr. Collis continued. "AmerisourceBergen's diligence, actions and thoughtfulness in navigating this pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven vital for all our stakeholders."
Second Quarter Fiscal Year 2020 Summary Results
| GAAP | Adjusted (Non-GAAP) | |
| Revenue | $47.4B | $47.4B |
| Gross Profit | $1.4B | $1.4B |
| Operating Expenses | $1,079M | $745M |
| Operating Income | $310M | $672M |
| Interest Expense, Net | $34M | $34M |
| Effective Tax Rate | (251.6)% | 21.5% |
| Net Income Attributable to ABC | $960M | $497M |
| Diluted Earnings Per Share | $4.64 | $2.40 |
| Diluted Shares Outstanding | 207M | 207M |
Below, AmerisourceBergen presents descriptive summaries of the Company's GAAP and adjusted (non-GAAP) quarterly results. In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. For more information related to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information Regarding non-GAAP Financial Measures following the tables.
Second Quarter GAAP Results
Second Quarter Adjusted (non-GAAP) Results
The comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit; PharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment; acquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain discrete tax benefits; and a gain on the sale of an equity investment.
The Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in Other for the purpose of reportable segment presentation. Other consists of operating segments that focus on global commercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI Animal Health (MWI).
Pharmaceutical Distribution Services Segment
Pharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior fiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market growth. Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.
Revenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in the prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier. Operating income in Other increased 8.4 percent to $108.3 million in the second quarter of fiscal 2020. This increase was primarily due to the performance of MWI and World Courier.
Recent Company Highlights & Milestones
Fiscal Year 2020 Expectations
The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available or cannot be reasonably estimated. Please refer to the Supplemental Information Regarding Non-GAAP Financial Measures following the tables for additional information.
Fiscal Year 2020 Expectations on an Adjusted (non-GAAP) Basis
AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company's continued strong performance and opportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal year. The Company now expects:
Additional expectations now include:
All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.
Dividend Declaration
The Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to stockholders of record at the close of business on May 18, 2020.
New Share Repurchase Authorization
In May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to purchase up to $500 million of its outstanding shares of common stock, subject to market conditions. As of March 31, 2020, the Company had $68.8 million remaining under the share repurchase program authorized in October 2018.
Conference Call & Slide Presentation
The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2020. A slide presentation for investors has also been posted on the Company's website at investor.amerisourcebergen.com. Participating in the conference call will be:
Steven H. Collis, Chairman, President & Chief Executive Officer
James F. Cleary, Executive Vice President & Chief Financial Officer
The dial-in number for the live call will be (866) 270-1533. From outside the United States, dial (412) 317-0797. No access code is required. The live call will also be webcast via the Company's website at investor.amerisourcebergen.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.
Replays of the call will be made available via telephone and webcast. A replay of the webcast will be posted on investor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. The telephone replay will also be available approximately one hour after the completion of the call and will remain available for seven days. To access the telephone replay from within the U.S., dial (877) 344-7529. From Canada, dial (855) 669-9658. From outside the United States and Canada, dial (412) 317-0088. The access code for the replay is 10142230.
Upcoming Investor Events
AmerisourceBergen management will be participating in the following investor conference in the coming months:
Goldman Sachs 41st Annual Global Healthcare Conference, June 9-11.
Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.
About AmerisourceBergen
AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work-and powered by our 22,000 associates-we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. The company is headquartered in Valley Forge, Pa. and has a presence in 50+ countries. Learn more at investor.amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking Statements
Certain of the statements contained in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with our former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the Company's operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.
AMERISOURCEBERGEN CORPORATION
(In thousands, except per share data)
| Three Months Ended March 31, 2020 | % of Revenue | Three Months Ended March 31, 2019 | % of Revenue | % Change | ||||||||||
| Revenue | $ | 47,417,639 | $ | 43,319,602 | 9.5% | |||||||||
| Cost of goods sold | 46,029,532 | 41,894,846 | 9.9% | |||||||||||
| Gross profit 1 | 1,388,107 | 2.93% | 1,424,756 | 3.29% | (2.6)% | |||||||||
| Operating expenses: | ||||||||||||||
| Distribution, selling, and administrative 2 | 693,413 | 1.46% | 628,036 | 1.45% | 10.4% | |||||||||
| Depreciation and amortization | 93,795 | 0.20% | 123,766 | 0.29% | (24.2)% | |||||||||
| Employee severance, litigation, and other 3 | 67,732 | 55,389 | ||||||||||||
| Impairment of PharMEDium assets | 223,652 | 570,000 | ||||||||||||
| Total operating expenses | 1,078,592 | 2.27% | 1,377,191 | 3.18% | (21.7)% | |||||||||
| Operating income | 309,515 | 0.65% | 47,565 | 0.11% | 550.7% | |||||||||
| Other income 4 | (1,109 | ) | (14,494 | ) | ||||||||||
| Interest expense, net | 34,421 | 43,275 | (20.5)% | |||||||||||
| Income before income taxes | 276,203 | 0.58% | 18,784 | 0.04% | 1,370.4% | |||||||||
| Income tax benefit 5 | (694,908 | ) | (9,289 | ) | ||||||||||
| Net income | 971,111 | 2.05% | 28,073 | 0.06% | 3,359.2% | |||||||||
| Net income attributable to noncontrolling interest | (10,834 | ) | (938 | ) | ||||||||||
| Net income attributable to AmerisourceBergen Corporation | $ | 960,277 | 2.03% | $ | 27,135 | 0.06% | 3,438.9% | |||||||
| Earnings per share: | ||||||||||||||
| Basic | $ | 4.68 | $ | 0.13 | 3,500.0% | |||||||||
| Diluted | $ | 4.64 | $ | 0.13 | 3,469.2% | |||||||||
| Weighted average common shares outstanding: | ||||||||||||||
| Basic | 205,370 | 210,934 | (2.6)% | |||||||||||
| Diluted | 207,062 | 212,563 | (2.6)% |
________________________________________
AMERISOURCEBERGEN CORPORATION
(In thousands, except per share data)
| Six Months Ended March 31, 2020 | % of Revenue | Six Months Ended March 31, 2019 | % of Revenue | % Change | ||||||||||
| Revenue | $ | 95,282,381 | $ | 88,712,054 | 7.4% | |||||||||
| Cost of goods sold | 92,663,060 | 85,989,718 | 7.8% | |||||||||||
| Gross profit 1 | 2,619,321 | 2.75% | 2,722,336 | 3.07% | (3.8)% | |||||||||
| Operating expenses: | ||||||||||||||
| Distribution, selling, and administrative 2 | 1,379,366 | 1.45% | 1,284,621 | 1.45% | 7.4% | |||||||||
| Depreciation and amortization | 198,310 | 0.21% | 246,266 | 0.28% | (19.5)% | |||||||||
| Employee severance, litigation, and other 3 | 107,041 | 96,061 | ||||||||||||
| Impairment of PharMEDium assets | 361,652 | 570,000 | ||||||||||||
| Total operating expenses | 2,046,369 | 2.15% | 2,196,948 | 2.48% | (6.9)% | |||||||||
| Operating income | 572,952 | 0.60% | 525,388 | 0.59% | 9.1% | |||||||||
| Other loss (income) 4 | 1,733 | (11,397 | ) | |||||||||||
| Interest expense, net | 65,428 | 85,445 | (23.4)% | |||||||||||
| Income before income taxes | 505,791 | 0.53% | 451,340 | 0.51% | 12.1% | |||||||||
| Income tax (benefit) expense 5 | (651,888 | ) | 31,514 | |||||||||||
| Net income | 1,157,679 | 1.21% | 419,826 | 0.47% | 175.8% | |||||||||
| Net (income) loss attributable to noncontrolling interest | (9,762 | ) | 961 | |||||||||||
| Net income attributable to AmerisourceBergen Corporation | $ | 1,147,917 | 1.20% | $ | 420,787 | 0.47% | 172.8% | |||||||
| Earnings per share: | ||||||||||||||
| Basic | $ | 5.58 | $ | 1.99 | 180.4% | |||||||||
| Diluted | $ | 5.54 | $ | 1.97 | 181.2% | |||||||||
| Weighted average common shares outstanding: | ||||||||||||||
| Basic | 205,693 | 211,503 | (2.7)% | |||||||||||
| Diluted | 207,293 | 213,275 | (2.8)% |
________________________________________
AMERISOURCEBERGEN CORPORATION
GAAP TO NON-GAAP RECONCILIATIONS
(in thousands, except per share data)
| Three Months Ended March 31, 2020 | |||||||||||||||||||||||||||||||||
| Gross Profit | Operating Expenses | Operating Income | Income Before Income Taxes | Income Tax (Benefit) Expense | Net Income Attributable to Noncontrolling Interest | Net Income Attributable to ABC | Diluted Earnings Per Share | ||||||||||||||||||||||||||
| GAAP | $ | 1,388,107 | $ | 1,078,592 | $ | 309,515 | $ | 276,203 | $ | (694,908 | ) | $ | (10,834 | ) | $ | 960,277 | $ | 4.64 | |||||||||||||||
| Gain from antitrust litigation settlements | (54 | ) | - | (54 | ) | (54 | ) | (111 | ) | - | 57 | - | |||||||||||||||||||||
| LIFO expense | 23,853 | - | 23,853 | 23,853 | 5,972 | - | 17,881 | 0.09 | |||||||||||||||||||||||||
| PharMEDium shutdown costs | 4,989 | (27,481 | ) | 32,470 | 32,470 | 8,107 | - | 24,363 | 0.12 | ||||||||||||||||||||||||
| Acquisition-related intangibles amortization | - | (26,670 | ) | 26,670 | 26,670 | 6,894 | (435 | ) | 19,341 | 0.09 | |||||||||||||||||||||||
| Employee severance, litigation, and other | - | (67,732 | ) | 67,732 | 67,732 | 16,978 | - | 50,754 | 0.25 | ||||||||||||||||||||||||
| Impairment of PharMEDium assets | - | (223,652 | ) | 223,652 | 223,652 | 56,156 | - | 167,496 | 0.81 | ||||||||||||||||||||||||
| Contingent consideration adjustment | - | 12,153 | (12,153 | ) | (12,153 | ) | (2,965 | ) | 7,511 | (1,677 | ) | (0.01 | ) | ||||||||||||||||||||
| Certain discrete tax benefits 1 | - | - | - | - | 741,015 | - | (741,015 | ) | (3.58 | ) | |||||||||||||||||||||||
| Adjusted Non-GAAP | $ | 1,416,895 | $ | 745,210 | $ | 671,685 | $ | 638,373 | $ | 137,138 | $ | (3,758 | ) | $ | 497,477 | $ | 2.40 | 2 | |||||||||||||||
| Adjusted Non-GAAP % change vs. prior year quarter | 7.5 | % | 6.2 | % | 8.9 | % | 11.2 | % | 11.1 | % | 10.7 | % | 13.7 | % |
| Percentages of Revenue: | GAAP | Adjusted Non-GAAP | ||
| Gross profit | 2.93% | 2.99% | ||
| Operating expenses | 2.27% | 1.57% | ||
| Operating income | 0.65% | 1.42% |
________________________________________
Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release.
AMERISOURCEBERGEN CORPORATION
GAAP TO NON-GAAP RECONCILIATIONS
(in thousands, except per share data)
| Three months ended March 31, 2019 | |||||||||||||||||||||||||||||||||
| Gross Profit | Operating Expenses | Operating Income | Income Before Income Taxes | Income Tax (Benefit) Expense | Net Income Attributable to Noncontrolling Interest | Net Income Attributable to ABC | Diluted Earnings Per Share | ||||||||||||||||||||||||||
| GAAP | $ | 1,424,756 | $ | 1,377,191 | $ | 47,565 | $ | 18,784 | $ | (9,289 | ) | $ | (938 | ) | $ | 27,135 | $ | 0.13 | |||||||||||||||
| Gain from antitrust litigation settlements | (51,976 | ) | - | (51,976 | ) | (51,976 | ) | (16,980 | ) | - | (34,996 | ) | (0.16 | ) | |||||||||||||||||||
| LIFO credit | (66,805 | ) | - | (66,805 | ) | (66,805 | ) | (17,137 | ) | - | (49,668 | ) | (0.23 | ) | |||||||||||||||||||
| PharMEDium remediation costs | 12,334 | (3,563 | ) | 15,897 | 15,897 | 4,927 | - | 10,970 | 0.05 | ||||||||||||||||||||||||
| New York State Opioid Stewardship Act | - | - | - | - | (944 | ) | - | 944 | - | ||||||||||||||||||||||||
| Acquisition-related intangibles amortization | - | (46,594 | ) | 46,594 | 46,594 | 13,800 | (437 | ) | 32,357 | 0.15 | |||||||||||||||||||||||
| Employee severance, litigation, and other | - | (55,389 | ) | 55,389 | 55,389 | 7,474 | - | 47,915 | 0.23 | ||||||||||||||||||||||||
| Impairment of PharMEDium assets | - | (570,000 | ) | 570,000 | 570,000 | 145,103 | - | 424,897 | 2.00 | ||||||||||||||||||||||||
| Gain on sale of an equity investment | - | - | - | (13,692 | ) | (3,485 | ) | - | (10,207 | ) | (0.05 | ) | |||||||||||||||||||||
| Adjusted Non-GAAP | $ | 1,318,309 | $ | 701,645 | $ | 616,664 | $ | 574,191 | $ | 123,469 | $ | (1,375 | ) | $ | 449,347 | $ | 2.11 | 1 |
| Percentages of Revenue: | GAAP | Adjusted Non-GAAP | ||
| Gross profit | 3.29% | 3.04% | ||
| Operating expenses | 3.18% | 1.62% | ||
| Operating income | 0.11% | 1.42% |
________________________________________
Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release.
AMERISOURCEBERGEN CORPORATION
GAAP TO NON-GAAP RECONCILIATIONS
(in thousands, except per share data)
| Six Months Ended March 31, 2020 | |||||||||||||||||||||||||||||||||
| Gross Profit | Operating Expenses | Operating Income | Income Before Income Taxes | Income Tax (Benefit) Expense | Net Income Attributable to Noncontrolling Interest | Net Income Attributable to ABC | Diluted Earnings Per Share | ||||||||||||||||||||||||||
| GAAP | $ | 2,619,321 | $ | 2,046,369 | $ | 572,952 | $ | 505,791 | $ | (651,888 | ) | $ | (9,762 | ) | $ | 1,147,917 | $ | 5.54 | |||||||||||||||
| Gain from antitrust litigation settlements | (8,546 | ) | - | (8,546 | ) | (8,546 | ) | (2,085 | ) | - | (6,461 | ) | (0.03 | ) | |||||||||||||||||||
| LIFO expense | 37,134 | - | 37,134 | 37,134 | 9,059 | - | 28,075 | 0.14 | |||||||||||||||||||||||||
| PharMEDium shutdown and remediation costs | 12,124 | (36,511 | ) | 48,635 | 48,635 | 11,864 | - | 36,771 | 0.18 | ||||||||||||||||||||||||
| Acquisition-related intangibles amortization | - | (60,236 | ) | 60,236 | 60,236 | 14,695 | (871 | ) | 44,670 | 0.22 | |||||||||||||||||||||||
| Employee severance, litigation, and other | - | (107,041 | ) | 107,041 | 107,041 | 26,114 | - | 80,927 | 0.39 | ||||||||||||||||||||||||
| Impairment of PharMEDium assets | - | (361,652 | ) | 361,652 | 361,652 | 88,227 | - | 273,425 | 1.32 | ||||||||||||||||||||||||
| Contingent consideration adjustment | - | 12,153 | (12,153 | ) | (12,153 | ) | (2,965 | ) | 7,511 | (1,677 | ) | (0.01 | ) | ||||||||||||||||||||
| Certain discrete tax benefits 1 | - | - | - | - | 741,015 | - | (741,015 | ) | (3.57 | ) | |||||||||||||||||||||||
| Adjusted Non-GAAP | $ | 2,660,033 | $ | 1,493,082 | $ | 1,166,951 | $ | 1,099,790 | $ | 234,036 | $ | (3,122 | ) | $ | 862,632 | $ | 4.16 | 2 | |||||||||||||||
| Adjusted Non-GAAP % change vs. prior year period | 5.5 | % | 4.2 | % | 7.2 | % | 9.9 | % | 12.3 | % | 8.9 | % | 11.8 | % |
| Percentages of Revenue: | GAAP | Adjusted Non-GAAP | ||
| Gross profit | 2.75% | 2.79% | ||
| Operating expenses | 2.15% | 1.57% | ||
| Operating income | 0.60% | 1.22% |
________________________________________
Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release.
AMERISOURCEBERGEN CORPORATION
GAAP TO NON-GAAP RECONCILIATIONS
(in thousands, except per share data)
| Six Months Ended March 31, 2019 | ||||||||||||||||||||||||||||||||
| Gross Profit | Operating Expenses | Operating Income | Income Before Income Taxes | Income Tax Expense | Net Loss Attributable to Noncontrolling Interest | Net Income Attributable to ABC | Diluted Earnings Per Share | |||||||||||||||||||||||||
| GAAP | $ | 2,722,336 | $ | 2,196,948 | $ | 525,388 | $ | 451,340 | $ | 31,514 | $ | 961 | $ | 420,787 | $ | 1.97 | ||||||||||||||||
| Gain from antitrust litigation settlements | (139,255 | ) | - | (139,255 | ) | (139,255 | ) | (35,450 | ) | - | (103,805 | ) | (0.49 | ) | ||||||||||||||||||
| LIFO credit | (69,834 | ) | - | (69,834 | ) | (69,834 | ) | (17,778 | ) | - | (52,056 | ) | (0.24 | ) | ||||||||||||||||||
| PharMEDium remediation costs | 30,245 | (6,147 | ) | 36,392 | 36,392 | 9,264 | - | 27,128 | 0.13 | |||||||||||||||||||||||
| New York State Opioid Stewardship Act | (22,000 | ) | - | (22,000 | ) | (22,000 | ) | (5,600 | ) | - | (16,400 | ) | (0.08 | ) | ||||||||||||||||||
| Acquisition-related intangibles amortization | - | (91,746 | ) | 91,746 | 91,746 | 23,355 | (943 | ) | 67,448 | 0.32 | ||||||||||||||||||||||
| Employee severance, litigation, and other | - | (96,061 | ) | 96,061 | 96,061 | 24,454 | - | 71,607 | 0.34 | |||||||||||||||||||||||
| Impairment of PharMEDium assets | - | (570,000 | ) | 570,000 | 570,000 | 145,103 | - | 424,897 | 1.99 | |||||||||||||||||||||||
| Gain on sale of an equity investment | - | - | - | (13,692 | ) | (3,485 | ) | - | (10,207 | ) | (0.05 | ) | ||||||||||||||||||||
| Tax reform 1 | - | - | - | - | 36,997 | - | (36,997 | ) | (0.17 | ) | ||||||||||||||||||||||
| Adjusted Non-GAAP | $ | 2,521,492 | $ | 1,432,994 | $ | 1,088,498 | $ | 1,000,758 | $ | 208,374 | $ | 18 | $ | 792,402 | $ | 3.72 |
| Percentages of Revenue: | GAAP | Adjusted Non-GAAP | ||
| Gross profit | 3.07% | 2.84% | ||
| Operating expenses | 2.48% | 1.62% | ||
| Operating income | 0.59% | 1.23% |
________________________________________
Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release.
AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)
| Three months ended March 31, | ||||||||||
| Revenue | 2020 | 2019 | % Change | |||||||
| Pharmaceutical Distribution Services | $ | 45,562,670 | $ | 41,676,164 | 9.3% | |||||
| Other | 1,876,593 | 1,665,429 | 12.7% | |||||||
| Intersegment eliminations | (21,624 | ) | (21,991 | ) | ||||||
| Revenue | $ | 47,417,639 | $ | 43,319,602 | 9.5% |
| Three months ended March 31, | ||||||||||
| Operating income | 2020 | 2019 | % Change | |||||||
| Pharmaceutical Distribution Services | $ | 563,097 | $ | 517,034 | 8.9% | |||||
| Other | 108,260 | 99,879 | 8.4% | |||||||
| Intersegment eliminations | 328 | (249 | ) | |||||||
| Total segment operating income | 671,685 | 616,664 | 8.9% | |||||||
| Gain from antitrust litigation settlements | 54 | 51,976 | ||||||||
| LIFO (expense) credit | (23,853 | ) | 66,805 | |||||||
| PharMEDium shutdown and remediation costs | (32,470 | ) | (15,897 | ) | ||||||
| Acquisition-related intangibles amortization | (26,670 | ) | (46,594 | ) | ||||||
| Employee severance, litigation, and other | (67,732 | ) | (55,389 | ) | ||||||
| Impairment of PharMEDium assets | (223,652 | ) | (570,000 | ) | ||||||
| Contingent consideration adjustment | 12,153 | - | ||||||||
| Operating income | $ | 309,515 | $ | 47,565 | ||||||
| Percentages of revenue: | ||||||||||
| Pharmaceutical Distribution Services | ||||||||||
| Gross profit | 2.32% | 2.38% | ||||||||
| Operating expenses | 1.08% | 1.14% | ||||||||
| Operating income | 1.24% | 1.24% | ||||||||
| Other | ||||||||||
| Gross profit | 19.15% | 19.60% | ||||||||
| Operating expenses | 13.38% | 13.60% | ||||||||
| Operating income | 5.77% | 6.00% | ||||||||
| AmerisourceBergen Corporation (GAAP) | ||||||||||
| Gross profit | 2.93% | 3.29% | ||||||||
| Operating expenses | 2.27% | 3.18% | ||||||||
| Operating income | 0.65% | 0.11% | ||||||||
| AmerisourceBergen Corporation (Non-GAAP) | ||||||||||
| Adjusted gross profit | 2.99% | 3.04% | ||||||||
| Adjusted operating expenses | 1.57% | 1.62% | ||||||||
| Adjusted operating income | 1.42% | 1.42% |
Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release.
AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)
| Six Months Ended March 31, | ||||||||||
| Revenue | 2020 | 2019 | % Change | |||||||
| Pharmaceutical Distribution Services | $ | 91,599,498 | $ | 85,420,545 | 7.2% | |||||
| Other | 3,723,577 | 3,336,367 | 11.6% | |||||||
| Intersegment eliminations | (40,694 | ) | (44,858 | ) | ||||||
| Revenue | $ | 95,282,381 | $ | 88,712,054 | 7.4% |
| Six Months Ended March 31, | ||||||||||
| Operating income | 2020 | 2019 | % Change | |||||||
| Pharmaceutical Distribution Services | $ | 954,791 | $ | 890,241 | 7.3% | |||||
| Other | 212,739 | 198,813 | 7.0% | |||||||
| Intersegment eliminations | (579 | ) | (556 | ) | ||||||
| Total segment operating income | 1,166,951 | 1,088,498 | 7.2% | |||||||
| Gain from antitrust litigation settlements | 8,546 | 139,255 | ||||||||
| LIFO (expense) credit | (37,134 | ) | 69,834 | |||||||
| PharMEDium shutdown and remediation costs | (48,635 | ) | (36,392 | ) | ||||||
| New York State Opioid Stewardship Act | - | 22,000 | ||||||||
| Acquisition-related intangibles amortization | (60,236 | ) | (91,746 | ) | ||||||
| Employee severance, litigation, and other | (107,041 | ) | (96,061 | ) | ||||||
| Impairment of PharMEDium assets | (361,652 | ) | (570,000 | ) | ||||||
| Contingent consideration adjustment | 12,153 | - | ||||||||
| Operating income | $ | 572,952 | $ | 525,388 | ||||||
| Percentages of revenue: | ||||||||||
| Pharmaceutical Distribution Services | ||||||||||
| Gross profit | 2.13% | 2.19% | ||||||||
| Operating expenses | 1.09% | 1.15% | ||||||||
| Operating income | 1.04% | 1.04% | ||||||||
| Other | ||||||||||
| Gross profit | 19.08% | 19.53% | ||||||||
| Operating expenses | 13.37% | 13.57% | ||||||||
| Operating income | 5.71% | 5.96% | ||||||||
| AmerisourceBergen Corporation (GAAP) | ||||||||||
| Gross profit | 2.75% | 3.07% | ||||||||
| Operating expenses | 2.15% | 2.48% | ||||||||
| Operating income | 0.60% | 0.59% | ||||||||
| AmerisourceBergen Corporation (Non-GAAP) | ||||||||||
| Adjusted gross profit | 2.79% | 2.84% | ||||||||
| Adjusted operating expenses | 1.57% | 1.62% | ||||||||
| Adjusted operating income | 1.22% | 1.23% |
Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release.
AMERISOURCEBERGEN CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31, | September 30, | ||||||
| 2020 | 2019 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 3,691,938 | $ | 3,374,194 | |||
| Accounts receivable, net | 14,210,170 | 12,386,879 | |||||
| Inventories | 11,102,566 | 11,060,254 | |||||
| Right to recover asset | 1,301,108 | 1,147,483 | |||||
| Income tax receivable | 699,494 | 5,859 | |||||
| Prepaid expenses and other | 175,374 | 157,385 | |||||
| Total current assets | 31,180,650 | 28,132,054 | |||||
| Property and equipment, net | 1,421,768 | 1,770,516 | |||||
| Goodwill and other intangible assets | 8,639,581 | 9,000,343 | |||||
| Other long-term assets | 800,263 | 269,067 | |||||
| Total assets | $ | 42,042,262 | $ | 39,171,980 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 30,719,987 | $ | 28,385,074 | |||
| Other current liabilities | 868,996 | 1,057,208 | |||||
| Short-term debt | 522,807 | 139,012 | |||||
| Total current liabilities | 32,111,790 | 29,581,294 | |||||
| Long-term debt | 3,622,387 | 4,033,880 | |||||
| Accrued income taxes | 279,403 | 284,075 | |||||
| Deferred income taxes | 1,843,910 | 1,860,195 | |||||
| Other long-term liabilities | 479,659 | 419,330 | |||||
| Total equity | 3,705,113 | 2,993,206 | |||||
| Total liabilities and equity | $ | 42,042,262 | $ | 39,171,980 |
AMERISOURCEBERGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Six Months Ended March 31, | |||||||
| 2020 | 2019 | ||||||
| Operating Activities: | |||||||
| Net income | $ | 1,157,679 | $ | 419,826 | |||
| Adjustments to reconcile net income to net cash provided by operating activities 1 | 643,981 | 820,403 | |||||
| Changes in operating assets and liabilities, excluding the effects of acquisitions: | |||||||
| Accounts receivable | (2,052,216 | ) | (880,805 | ) | |||
| Inventories | (152,359 | ) | (420,190 | ) | |||
| Accounts payable | 2,395,847 | 1,350,728 | |||||
| Other 2 | (997,225 | ) | (186,630 | ) | |||
| Net cash provided by operating activities | 995,707 | 1,103,332 | |||||
| Investing Activities: | |||||||
| Capital expenditures | (144,382 | ) | (161,488 | ) | |||
| Cost of equity investments and acquired companies, net of cash acquired | (30,580 | ) | (52,398 | ) | |||
| Other | 7,162 | 2,659 | |||||
| Net cash used in investing activities | (167,800 | ) | (211,227 | ) | |||
| Financing Activities: | |||||||
| Net borrowings (repayments) | 947 | (16,017 | ) | ||||
| Purchases of common stock 3 | (407,152 | ) | (347,959 | ) | |||
| Exercises of stock options | 76,757 | 37,590 | |||||
| Cash dividends on common stock | (170,541 | ) | (170,428 | ) | |||
| Other | (10,174 | ) | (12,057 | ) | |||
| Net cash used in financing activities | (510,163 | ) | (508,871 | ) | |||
| Increase in cash and cash equivalents | 317,744 | 383,234 | |||||
| Cash and cash equivalents at beginning of period | 3,374,194 | 2,492,516 | |||||
| Cash and cash equivalents at end of period | $ | 3,691,938 | $ | 2,875,750 |